Last reviewed · How we verify
CAL02
CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.
CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines. Used for Treatment of rheumatoid arthritis.
At a glance
| Generic name | CAL02 |
|---|---|
| Sponsor | Eagle Pharmaceuticals, Inc. |
| Drug class | CDK9 inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Inflammation |
| Phase | Phase 2 |
Mechanism of action
By inhibiting CDK9, CAL02 decreases the production of pro-inflammatory cytokines, which are involved in the development and progression of various inflammatory diseases. This mechanism of action suggests that CAL02 may be effective in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis or psoriasis.
Approved indications
- Treatment of rheumatoid arthritis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia (PHASE2)
- Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAL02 CI brief — competitive landscape report
- CAL02 updates RSS · CI watch RSS
- Eagle Pharmaceuticals, Inc. portfolio CI